Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA™ (bevacizumab-vikg)
wet AMD
Countdown
23days
FDA decision · Jul 29, 2026
What's at stake
The FDA's approval decision on ONS-5010/LYTENAVA™ (bevacizumab-vikg) for wet AMD is due Jul 29, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“As indicated in the formal decision, it is anticipated that this will be a Class 1 resubmission with a PDUFA date and decision expected within 60 days of FDA’s receipt of the resubmission.”